ERBB3

erb-b2 receptor tyrosine kinase 3

Identifier: CI-GENE-00044906
Entity page: /gene/ERBB3 ↗
Edges: 61

Neighbours: 13 cancers15 variants9 drugs
Drawn: 37 of 37 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,149 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
ERBB3 associated with …ASSOCIATED_WITH5 of 5
→ associated with	Transitional Cell Carcinomahistology 3 source records aggregated	supports	B	Transitional Cell Carcinoma	3	Curated	civic	graph →
→ associated with	Malignant Colorectal Neoplasmsubtype	supports

ERBB3 targets …TARGETS9 of 9
← targets	Zenocutuzumab-zbcomonoclonal_antibody	—	INHIBITOR	—	1	Curated	chembl	graph →
← targets	Vandetanibsmall_molecule	—	INHIBITOR	—	1	Curated	chembl	graph →
← targets	Tarloxotinibsmall_molecule	—	INHIBITOR	—	1	Curated	chembl	graph →
← targets	Seribantumabmonoclonal_antibody	—	ANTAGONIST\|INHIBITOR	—	1	Curated	chembl	graph →
← targets	Poziotinibsmall_molecule	—	INHIBITOR	—	1	Curated	chembl	graph →
← targets	Patritumab Deruxtecanadc	—	BINDING AGENT	—	1	Curated	chembl	graph →
← targets	Patritumabmonoclonal_antibody	—	INHIBITOR	—	1	Curated	chembl	graph →
← targets	Lumretuzumabmonoclonal_antibody	—	INHIBITOR	—	1	Curated	chembl	graph →
← targets	Duligotuzumabmonoclonal_antibody	—	INHIBITOR	—	1	Curated	chembl	graph →

ERBB3 targets …TARGETS9 of 9

← targets

Zenocutuzumab-zbcomonoclonal_antibody

—

INHIBITOR

—

Curated

ERBB3 has variant …HAS_VARIANTderived15 of 39show all (up to 200)
→ has variant	Overexpressionexpression 4 accepted CIViC evidence items	—	—	Malignant Neoplasm,Malignant Colorectal Neoplasm,HER2-Positive Breast Carcinoma	4	Curated	civic	graph →
→ has variant	EXPRESSIONexpression 2 accepted CIViC evidence items	—	—	Malignant Neoplasm,Pancreatic Ductal Adenocarcinoma	2	Curated	civic	graph →
→ has variant	G284RSNV 1 accepted CIViC evidence items	—	—	Transitional Cell Carcinoma	1	Curated	civic	graph →
→ has variant	Mutationother 1 accepted CIViC evidence items	—	—	Malignant Colorectal Neoplasm	1	Curated	civic	graph →
→ has variant	R103GSNV 1 accepted CIViC evidence items	—	—	Transitional Cell Carcinoma	1	Curated	civic	graph →
→ has variant	V104MSNV 1 accepted CIViC evidence items	—	—	Transitional Cell Carcinoma	1	Curated	civic	graph →
→ has variant	V855ASNV 1 accepted CIViC evidence items	—	—	Lung Non-Small Cell Carcinoma	1	Curated	civic	graph →
→ has variant	A232VSNV no accepted CIViC evidence item (variant record only)	—	—	not mapped	0	Observed	civic	graph →
→ has variant	D297YSNV no accepted CIViC evidence item (variant record only)	—	—	not mapped	0	Observed	civic	graph →
→ has variant	E928GSNV no accepted CIViC evidence item (variant record only)	—	—	not mapped	0	Observed	civic	graph →
→ has variant	NM_001982.4(ERBB3):c.180G>A (p.Met60Ile)SNV no accepted CIViC evidence item (variant record only)	—	—	not mapped	0	Observed	civic	graph →
→ has variant	NM_001982.4(ERBB3):c.1911C>T (p.Ile637=)SNV no accepted CIViC evidence item (variant record only)	—	—	not mapped	0	Observed	civic	graph →
→ has variant	NM_001982.4(ERBB3):c.237G>A (p.Trp79Ter)SNV no accepted CIViC evidence item (variant record only)	—	—	not mapped	0	Observed	civic	graph →
→ has variant	NM_001982.4(ERBB3):c.2460+28A>GSNV no accepted CIViC evidence item (variant record only)	—	—	not mapped	0	Observed	civic	graph →
→ has variant	NM_001982.4(ERBB3):c.2782G>A (p.Glu928Lys)SNV no accepted CIViC evidence item (variant record only)	—	—	not mapped	0	Observed	civic	graph →

ERBB3 altered in cohorts of …ALTERED_INderived8 of 8
→ altered in cohorts of	Adrenal Cortical Carcinoma 68 / 92 cases (74 %) · ssm · TCGA-ACC	—	—	Adrenal Cortical Carcinoma	1	Observed	gdc	graph →
→ altered in cohorts of	Endometrial Carcinoma 31 / 181 cases (17 %) · ssm · ucec_ccr_msk_2022 · largest of 2 cohorts	—	—	Endometrial Carcinoma	2	Observed	cbioportal	graph →
→ altered in cohorts of	Bladder Urothelial Carcinoma 65 / 474 cases (14 %) · ssm · blca_msk_tcga_2020 · largest of 8 cohorts	—	—	Bladder Urothelial Carcinoma	8	Observed	cbioportal	graph →
→ altered in cohorts of	Invasive Breast Carcinoma 40 / 527 cases (7.6 %) · ssm · brca_msk_2025	—	—	Invasive Breast Carcinoma	1	Observed	cbioportal	graph →
→ altered in cohorts of	Gastric Adenocarcinoma 35 / 478 cases (7.3 %) · ssm · stad_tcga · largest of 4 cohorts	—	—	Gastric Adenocarcinoma	4	Observed	cbioportal	graph →
→ altered in cohorts of	Gastroesophageal Junction Adenocarcinoma 21 / 341 cases (6.2 %) · ssm · egc_msk_2017	—	—	Gastroesophageal Junction Adenocarcinoma	1	Observed	cbioportal	graph →
→ altered in cohorts of	Colorectal Adenocarcinoma 20 / 339 cases (5.9 %) · ssm · rectal_msk_2019	—	—	Colorectal Adenocarcinoma	1	Observed	cbioportal	graph →
→ altered in cohorts of	Rectal Adenocarcinoma 389 / 7,237 cases (5.4 %) · ssm · crc_msk_2026	—	—	Rectal Adenocarcinoma	1	Observed	cbioportal	graph →

Radial view

Every edge, grouped by relationship

Paths